MedTech Terms
    The authoritative reference
    All terms
    ReimbursementQuality SystemClinical EvidenceGlobal MarketsHospital Buyer & ReimbursementJCA

    Joint Clinical Assessment

    EU-wide clinical assessment of high-risk medical devices and IVDs.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

    Definition

    Under the EU HTA Regulation (EU) 2021/2282, the Joint Clinical Assessment provides a single clinical evaluation across EU member states for selected high-risk devices and IVDs, beginning 2026 for devices, with national pricing and reimbursement decisions remaining country-specific. JCAs cover clinical effectiveness and safety compared with relevant alternatives, not pricing, and member states must give the report due consideration in national HTA. Devices are selected by the HTA Coordination Group from high-risk devices that went through MDR or IVDR expert panel review. Developers can request joint scientific consultations to plan their evidence early.
    What the regulation says
    The EU HTA Regulation 2021/2282 mandates the Joint Clinical Assessment (JCA) to streamline clinical evaluations for certain high-risk medical devices and IVDs across the European Union. This process, beginning in 2026 for devices, aims to reduce the need for multiple national clinical assessments, as outlined in the regulation, while pricing and reimbursement decisions remain at the discretion of individual member states.

    What this means in practice

    Aims to reduce duplicate national clinical assessments. PICO definition, comparator selection, and evidence package are critical.

    Examples

    • A manufacturer planning to launch a Class III implantable device in the EU must prepare their clinical evidence according to JCA requirements for submission by 2026.
    • A Notified Body advises a client that their novel IVD for cancer diagnosis will be subject to JCA, requiring a comprehensive PICO-driven evidence submission.
    • During a strategic planning meeting, a MedTech company discusses how a successful JCA could accelerate market access across several EU countries, even though reimbursement will still be negotiated nationally.
    Common pitfalls
    • •Failing to understand which devices are subject to JCA can lead to delays in market access.
    • •Ignoring the PICO (Population, Intervention, Comparator, Outcome) framework requirements can result in an inadequate evidence package.
    • •Assuming that a positive JCA will guarantee reimbursement at the national level is a common misconception, as national authorities retain pricing and reimbursement autonomy.
    • •Neglecting to prepare for the specific data and methodological requirements of JCA can lead to significant rework during the assessment process.

    Frequently asked questions

    The primary goal is to reduce duplicate clinical assessments for high-risk medical devices and IVDs across EU member states, fostering a more harmonized approach to evidence evaluation.

    Related terms

    Grouped by theme
    Cited by

    Where this term appears across MedTech Terms.

    Sources

    1 source

    Sources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

    Official citation replacements checked: . Medicare documents support Medicare coding, coverage or payment context, not every payer policy or CPT editorial procedure. Citation replacement does not change the full term review date.

    Tier 2Regulator guidance and consensus· 1
    Link health: 1 verified· last checked 2026-06-20
    1. 1
      EU HTA Regulation
      Tier 2 Verified
      European Commissionhealth.ec.europa.eu

    Inline markers like [1] jump to the matching reference above.